Clinical Trials
133 trialsNCT05599048 2026-05-27
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
University of California, San Francisco
Phase 1/2 Recruiting
NCT07226349 2026-05-27
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07414836 2026-05-27
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07128303 2026-05-26
Study of GS-5319 in Adults With Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT05981703 2026-05-22
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06589596 2026-05-22
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06598800 2026-05-22
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05170958 2026-05-15
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT05329103 2026-05-15
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Peel Therapeutics Inc
Phase 1 Recruiting
NCT05901285 2026-05-14
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Vaxiion Therapeutics
Phase 1 Recruiting
NCT07182591 2026-05-14
A Study of DS5361b in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT06625593 2026-05-11
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05038150 2026-05-05
Study of SGN1 in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05103345 2026-05-05
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT07298772 2026-05-01
A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT07300943 2026-05-01
Study in Advanced Solid Tumor Patients
Callio Therapeutics
Phase 1/2 Recruiting
NCT06833008 2026-04-30
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT05451602 2026-04-28
HEC169096 in Participants With Advanced Solid Tumors
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Recruiting
NCT05687682 2026-04-28
Safety of AM-928 Infusion in Advanced Solid Tumors
AcadeMab Biomedical Inc.
Phase 1 Recruiting
NCT06260514 2026-04-23
ACESOT-1051
Aprea Therapeutics
Phase 1 Recruiting
NCT04855656 2026-04-20
MYTHIC
Debiopharm International SA
Phase 1 Recruiting
NCT06597721 2026-04-17
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
Phase 1 Recruiting
NCT07380334 2026-04-16
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06220864 2026-04-14
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT06143774 2026-04-13
Study of TRX-920 for Patients With Advanced Solid Tumors
TaiRx, Inc.
Phase 1 Recruiting
NCT06352359 2026-04-13
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Recruiting
NCT06635785 2026-04-09
BiPAVE-001
OncoC4, Inc.
Phase 1/2 Recruiting
NCT06911827 2026-04-07
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT06672185 2026-04-03
ARC101 in Advanced Solid Tumors
Third Arc Bio
Phase 1 Recruiting
NCT06953323 2026-03-27
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06253130 2026-03-23
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Eikon Therapeutics
Phase 1/2 Recruiting
NCT06973863 2026-02-13
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
PharmaEngine
Phase 1 Recruiting
NCT06750185 2026-02-11
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
BioNTech SE
Phase 1 Recruiting
NCT06244485 2026-02-04
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Daiichi Sankyo
Phase 1 Recruiting
NCT05443126 2026-02-03
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Ellipses Pharma
Phase 1/2 Recruiting
NCT06302426 2026-01-16
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
Phase 1 Recruiting
NCT06859762 2026-01-14
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT06298058 2026-01-07
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT06512116 2026-01-07
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT05584800 2026-01-05
Study of ZGGS18 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06938880 2026-01-05
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT07124117 2026-01-05
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Recruiting
NCT05007782 2025-12-29
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT05306132 2025-12-23
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06825494 2025-12-18
Clinical Studies for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT06488950 2025-12-16
A Study of TIL in Advanced Solid Tumors (DFGD)
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1 Recruiting
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT07256782 2025-12-01
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT05547321 2025-11-25
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
Phase 1 Recruiting